Literature DB >> 8132662

The short-term activation of a rolipram-sensitive, cAMP-specific phosphodiesterase by thyroid-stimulating hormone in thyroid FRTL-5 cells is mediated by a cAMP-dependent phosphorylation.

C Sette1, S Iona, M Conti.   

Abstract

To elucidate the mechanism causing the transient accumulation of intracellular cAMP in the FRTL-5 thyroid cell line, the short-term effect of thyroid-stimulating hormone (TSH) on phosphodiesterase (PDE) activity was studied. Together with an increase in cAMP levels, TSH produced a significant increase in total PDE activity as early as 3 min, with a maximal stimulation reached after 15 min. This short-term increase in PDE activity was dependent on the TSH concentration (ED50 = 4 x 10(-11) M TSH). Forskolin and dibutyryl cAMP produced an even larger stimulation than that produced by TSH, suggesting that the effect of TSH is mediated by cAMP. To determine the properties of the PDE forms activated by TSH, antibodies specific for the cAMP-PDEs were used to immunoprecipitate the PDEs present in control cells, and cells incubated for 15 min in the presence of 10 nM TSH. Comparison of the activity recovered in the immunoprecipitation pellets demonstrated that TSH produced more than a 2.5-fold increase in the cAMP-PDE form(s) recognized by this antibody. Conversely, the activity remaining in the supernatants was not affected by the TSH treatment. Most of the activity recovered in the immunoprecipitation pellets (90%) was inhibited by 10 microM Rolipram, an inhibitor specific for the high affinity cAMP-PDEs. No TSH stimulation of the Rolipram-insensitive PDE activity could be observed under these conditions. Western blot analyses with two different cAMP-PDE specific antibodies showed that a 15-min stimulation with TSH induced the appearance of a new band with electrophoretic mobility slower than the polypeptide present in unstimulated cells. The appearance of this band did not require ongoing protein synthesis because it occurred in the presence of cycloheximide. Metabolic [32P]orthophosphate labeling of intact FRTL-5 cells indicated that the TSH treatment caused an increased 32P incorporation into a polypeptide that co-purified with the stimulated PDE activity and had an electrophoretic mobility identical to that of the cAMP-PDE. Okadaic acid, a potent inhibitor of protein phosphatase 1 and protein phosphatase 2A, elicited a potentiation of the TSH-stimulated PDE activity. The stimulating of a PDE with the same immunological properties and Rolipram sensitivity as the cAMP-PDE stimulated by TSH in the intact cells was reproduced, in a cell-free system, by incubating soluble extracts from FRTL-5 cells with the catalytic subunit of cAMP-dependent protein kinase. These data provide evidence that TSH produces a rapid activation of a cAMP-PDE in the FRTL-5 cells through a cAMP-dependent phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8132662

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  32 in total

1.  A-kinase anchoring proteins regulate compartmentalized cAMP signaling in airway smooth muscle.

Authors:  Sarah J Horvat; Deepak A Deshpande; Huandong Yan; Reynold A Panettieri; Juan Codina; Thomas D DuBose; Wenkuan Xin; Thomas C Rich; Raymond B Penn
Journal:  FASEB J       Date:  2012-05-30       Impact factor: 5.191

2.  Evolutionarily conserved role of calcineurin in phosphodegron-dependent degradation of phosphodiesterase 4D.

Authors:  Hong Zhu; Hee Yun Suk; Raymond Y L Yu; Deborah Brancho; Opeyemi Olabisi; Teddy T C Yang; XiaoYong Yang; Jialin Zhang; Mustapha Moussaif; Jorge L Durand; Linda A Jelicks; Ja-Young Kim; Philipp E Scherer; Philippe G Frank; Michael P Lisanti; John W Calvert; Mark R Duranski; David J Lefer; Elaine Huston; George S Baillie; Miles D Houslay; Jeffrey D Molkentin; Jianping Jin; Chi-Wing Chow
Journal:  Mol Cell Biol       Date:  2010-07-20       Impact factor: 4.272

Review 3.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

4.  Alterations of pre- and postsynaptic noradrenergic signaling in a rat model of adriamycin-induced cardiotoxicity.

Authors:  Miran Kenk; James T Thackeray; Stephanie L Thorn; Karan Dhami; Benjamin J Chow; Kathy J Ascah; Jean N DaSilva; Rob S Beanlands
Journal:  J Nucl Cardiol       Date:  2010-02-25       Impact factor: 5.952

5.  Receptor-mediated stimulation of lipid signalling pathways in CHO cells elicits the rapid transient induction of the PDE1B isoform of Ca2+/calmodulin-stimulated cAMP phosphodiesterase.

Authors:  S Spence; G Rena; M Sullivan; S Erdogan; M D Houslay
Journal:  Biochem J       Date:  1997-01-01       Impact factor: 3.857

6.  Cellular mechanisms underlying prostaglandin-induced transient cAMP signals near the plasma membrane of HEK-293 cells.

Authors:  Thomas C Rich; Wenkuan Xin; Celine Mehats; Kathryn A Hassell; Leslie A Piggott; Xuan Le; Jeffrey W Karpen; Marco Conti
Journal:  Am J Physiol Cell Physiol       Date:  2006-08-09       Impact factor: 4.249

7.  Molecular cloning and transient expression in COS7 cells of a novel human PDE4B cAMP-specific phosphodiesterase, HSPDE4B3.

Authors:  E Huston; S Lumb; A Russell; C Catterall; A H Ross; M R Steele; G B Bolger; M J Perry; R J Owens; M D Houslay
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

8.  Phosphodiesterase 10A Is Tethered to a Synaptic Signaling Complex in Striatum.

Authors:  Corina Russwurm; Doris Koesling; Michael Russwurm
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

9.  RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5.

Authors:  Graeme B Bolger
Journal:  Cell Signal       Date:  2015-08-06       Impact factor: 4.315

10.  Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms.

Authors:  M Takahashi; R Terwilliger; C Lane; P S Mezes; M Conti; R S Duman
Journal:  J Neurosci       Date:  1999-01-15       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.